Conflict of Interest: Drs. Tiede, Vallejo and Brown are consultants and speakers for Nevro Corporation and have received compensation in the form of consultant fees and/or stock options. Drs. Tiede, Brown, Gekht, Vallejo, Morgan, and Yearwood are/were sponsored investigators of Nevro Corporation.
Prospective Nonrandomized Trial
Novel Spinal Cord Stimulation Parameters in Patients with Predominant Back Pain
Version of Record online: 21 FEB 2013
© 2013 International Neuromodulation Society
Neuromodulation: Technology at the Neural Interface
Volume 16, Issue 4, pages 370–375, July/August 2013
How to Cite
Tiede, J., Brown, L., Gekht, G., Vallejo, R., Yearwood, T. and Morgan, D. (2013), Novel Spinal Cord Stimulation Parameters in Patients with Predominant Back Pain. Neuromodulation: Technology at the Neural Interface, 16: 370–375. doi: 10.1111/ner.12032
For more information on author guidelines, an explanation of our peer review process, and conflict of interest informed consent policies, please go to http://www.wiley.com/bw/submit.asp?ref=1094-7159&site=1
The views expressed in this article are those of the authors and do not necessarily reflect the official policy or position of the Department of the Army or the U.S. Government.
- Issue online: 5 AUG 2013
- Version of Record online: 21 FEB 2013
- Manuscript Accepted: 3 JAN 2013
- Manuscript Revised: 20 OCT 2012
- Manuscript Received: 27 APR 2012
- Nevro Corp., Menlo Park, CA
- Axial back pain;
- failed back surgery syndrome;
- high frequency;
- low back pain;
- spinal cord stimulation
To examine the feasibility of novel high-frequency spinal cord stimulation therapy in a cohort of patients with chronic predominant back pain during a four day, percutaneous trial.
Prospective, multicenter open label pilot trial. Setting and Patients: Twenty-four patients with back pain greater than leg pain who were candidates for spinal cord stimulation were trialed at five U.S. centers.
Patients completed a percutaneous trial with a commercially available spinal cord stimulator. The implanted leads were then connected to the novel external stimulation device and patients were trialed for an additional four days.
Pain intensity ratings, subjective descriptions, and patients' preference.
There was significant improvement from baseline in overall pain scores (8.68 to 2.03, [p < 0.001]) and back pain scores (8.12 to 1.88, [p < 0.001]) with the investigational stimulation. The investigational stimulation was preferred to the commercially available systems in 21 of 24 patients (88%).
Patients with predominant back pain reported a substantial reduction in overall pain and back pain when trialed with high-frequency spinal cord stimulation therapy.